Apr 6, 2022 8:00 am EDT Ocuphire Pharma to Present at Wet AMD & DME Drug Development Summit in Boston, MA
Mar 29, 2022 7:00 am EDT Ocuphire Announces Positive Topline Results from MIRA-3 Phase 3 FDA Registration Trial for Nyxol® in the Reversal of Mydriasis
Mar 24, 2022 8:00 am EDT Ocuphire Announces Financial Results for the Fourth Quarter and Year Ended December 31, 2021 and Provides Corporate Update
Mar 16, 2022 7:30 am EDT Ocuphire Completes Enrollment of Over 100 Subjects in 24-Week ZETA-1 Phase 2b Trial of Oral APX3330 for the Treatment of Diabetic Retinopathy
Mar 8, 2022 8:00 am EST Ocuphire Completes Enrollment in MIRA-4 Pediatric Safety Trial Evaluating Nyxol® for Reversal of Mydriasis
Feb 8, 2022 8:00 am EST Ocuphire Completes Enrollment in MIRA-3 Pivotal Phase 3 Clinical Trial for Nyxol® in RM and Announces Two Upcoming Medical Conference Presentations
Jan 31, 2022 6:00 am EST Ocuphire Presenting New Data and Updates on APX3330 and Nyxol® Clinical Programs at Virtual Investor R&D Day